ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability,
PK, and immunogenicity of an ADG126-pembrolizumab combination regimen in patients with
advanced/metastatic solid tumors.